Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE (NASDAQ: EVO; Frankfurt: EVT) is a life science company focused on drug discovery and development, and its news flow reflects ongoing activity across partnerships, platforms and biologics. Company updates frequently highlight progress in strategic collaborations, such as multi-target kidney disease programs with Bayer, protein degradation and neuroscience alliances with Bristol Myers Squibb, and technology-focused agreements with Sandoz.
Investors following EVO news can expect announcements on clinical and preclinical milestones, including the advancement of monoclonal antibody programs into Phase 2 trials and Investigational New Drug acceptances for molecular glue degraders. Evotec also reports on grants and global health initiatives, for example Gates Foundation support for Just - Evotec Biologics’ J.MD™ molecular design service to improve the developability and affordability of monoclonal antibodies for infectious diseases.
News from Just - Evotec Biologics often centers on biologics development, continuous manufacturing technologies and the evolution of its asset-lighter model. This includes transactions such as the sale of the Toulouse site to Sandoz combined with an indefinite license to Evotec’s continuous manufacturing platform, as well as updates on revenue growth with a broadened customer base.
Regular corporate communications also cover financial results, guidance updates, cost reduction initiatives and organizational changes, such as segment renaming to Discovery & Preclinical Development and senior leadership appointments in communications and investor relations. For readers tracking EVO stock, this news page provides a consolidated view of how Evotec’s partnerships, platforms and strategic transactions are progressing over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
RenovoRx, a biopharmaceutical firm focused on localized cancer treatment, has appointed Leesa Gentry as the new Senior Vice President of Clinical Operations. Gentry, an expert with 29 years of experience in clinical trials management, is the fourth executive added to the management team recently. Her past roles include Senior Vice President at Evotec and significant contributions at PPD and Otsuka. The company is buoyed by positive interim data from its Phase III clinical trial on pancreatic cancer treatment, RenovoGemTM. CEO Shaun Bagai expressed confidence in Gentry's ability to advance the company's clinical trials, enhancing its mission to improve patient outcomes in oncology.
Evotec SE has confirmed the integrity of its operations following a cyber attack detected on April 6, 2023. Immediate actions were taken to secure all IT systems, which were temporarily taken offline to prevent data breaches. A forensic examination is currently being conducted by external experts to assess the situation. Despite the incident, business continuity has been maintained across all global sites, ensuring that services remain available to partners, albeit with potential delays in communication. Evotec has informed relevant authorities and will continue to update stakeholders through its website. The company remains committed to protecting data integrity and is implementing solutions to improve communication efficiency.
Evotec SE experienced a cyber attack on its IT systems on April 6, 2023. In response, the company proactively shut down and disconnected its systems from the Internet to prevent potential data breaches and corruption. Currently, the systems are under examination, and the company is assessing the impact of the attack while ensuring the highest standards of data integrity are maintained. Evotec has not reported any confirmed data loss or breaches at this time.
Evotec SE has extended and expanded its strategic partnership with Bristol Myers Squibb (BMY) for an additional 8 years, aimed at developing therapies for neurodegenerative diseases. This collaboration builds on their productive history since 2016, addressing significant unmet medical needs. The deal includes a $50 million upfront payment, milestone payments, and tiered royalties on product sales, with a deal potential of $4 billion. This partnership aims to leverage Evotec's precision medicine platforms to enhance drug discovery and development for debilitating neurological conditions.
Evotec SE reported a 22% increase in group revenues for the fiscal year 2022, reaching €751.4 million, exceeding its targets. The adjusted Group EBITDA was €101.7 million. The company's base business surged by 30% to €725.3 million. Positive developments include an extended alliance with Bristol Myers Squibb and multiple new strategic partnerships in various therapeutic areas. For 2023, Evotec forecasts revenues between €820 - €840 million and an adjusted EBITDA of €115 - €130 million.